Highest-materiality recent filing
Pluri gets EIB nod for loan talks; no enforcement until July 3 on €20M maturing today
€20M EIB loan at 4% interest matured on June 1, 2026; only first tranche of €50M facility was drawn.
Pluri receives Nasdaq delisting notice for failure to meet $35M market value of listed securities
Nasdaq notified Pluri on Jan. 20, 2026 that its market value of listed securities fell below the required $35M minimum.
Pluri raises $2.5M via private placement to director; appoints Chairman
Enters securities purchase agreement for 625,000 common shares and warrants at $4.00/unit; gross proceeds ~$2.5M.
Pluri loses director Birger, triggering Nasdaq audit committee non-compliance with cure period
Doron Birger not re-elected at June 30 annual meeting; received 1,270,717 for, 2,720,350 against.
Pluri regains Nasdaq compliance on market value requirement; delisting risk resolved
On May 7, 2025, Nasdaq notified Pluri that it has regained compliance with Listing Rule 5550(b)(2) – market value of listed securities >= $35M for 10 consecutive business days (Apr 22 – May 6).
Pluri exchanges 976,139 shares for pre-funded warrants exercisable after shareholder approval
Pluri amended the Jan 2025 Securities Purchase Agreement with Chutzpah Holdings (Alejandro Weinstein, director) to exchange 976,139 common shares for pre-funded warrants.
Pluri Biotech Ltd. received termination notice from NIAID for a $4.2M contract awarded July 2023 to develop PLX-R18 for Hematopoietic Acute Radiation Syndrome.
Pluri to acquire 71.1% of Kokomodo for $4.5M in stock (12.14% dilution); related party deal
Purchase price $4.5M payable in 976,139 Pluri common shares (12.14% of fully diluted shares as of Jan 23, 2025).
Pluri raises $3.5M via private placement at $4.61/share with warrants to existing shareholder
Gross proceeds of ~$3.5M from sale of 759,219 shares at $4.61 each.
Pluri raises $6.5M private placement, signs term sheet to acquire 71% of Kokomodo for $4.5M in stock
Private placement: 1,383,948 common shares at $4.61 each, plus pre-funded and common warrants; gross proceeds ~$6.5M.
Previously reported non-compliance with Nasdaq Listing Rule 5550(b)(1) requiring $2.5M stockholders' equity.
Pluri receives Nasdaq delisting notice for failing $2.5M equity requirement
Nasdaq notified Pluri on Nov 25, 2024 of noncompliance with Listing Rule 5550(b)(1) for stockholders' equity below $2.5M.
Pluri Inc. regains Nasdaq compliance on stockholders' equity requirement
Received Nasdaq letter on Sept 26, 2024 confirming regained compliance with $2.5M stockholders' equity requirement.
Pluri receives Nasdaq extension to Nov 24, 2024 to regain $2.5M equity requirement
Deficiency letter issued May 28, 2024 for failing Nasdaq's $2.5M stockholders' equity minimum.
Pluri signs €1M proof-of-concept agreement with international agriculture corporation
Agreement value of €1 million, payable in three installments; first upon signing.
Pluri's subsidiary Ever After Foods raises $10M; license expanded to seafood
Ever After Foods raised $10M in private placement; Pluri invested $1,250,000.
Pluri receives Nasdaq deficiency notice for failing to meet $2.5M min equity requirement
Received deficiency letter from Nasdaq on May 28, 2024 for non-compliance with minimum stockholders' equity of $2.5M.
On July 2, 2024, the Board of Directors of the Company appointed Liat Zalts, age 40, to serve as the Company’s Chief Financial Officer and Treasurer effective as of September 30, 2024.
On June 30, 2024, Ms. Chen Franco-Yehuda notified Pluri Inc. (the “Company”) of her resignation from her position as Chief Financial Officer, Treasurer and Secretary of the Company, which will become effective as of September 30, 2024.
Max materiality 0.85 · Median 0.60 · Most common event other_material